Jiangsu, China

Lei Chen

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.7

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Lei Chen: Innovator in Pharmaceutical Chemistry

Introduction

Lei Chen, an accomplished inventor based in Jiangsu, China, has made significant contributions to the field of pharmaceutical chemistry. With a portfolio of three patents, his innovations focus on the development of new compounds with pharmacological applications, particularly in treating diseases mediated by specific receptors.

Latest Patents

Lei Chen's latest patents demonstrate his expertise and commitment to advancing medical science. The first patent describes a sulfonyl-substituted bicyclic compound, which acts as a RORγ inhibitor. This compound exhibits notable inhibitory activity and holds promise for treating various diseases associated with the RORγ receptor in mammals. The second patent pertains to a pyrrole sulfonamide derivative, outlining its preparation method and medical applications. This novel derivative serves as a therapeutic agent, particularly as a gastric acid secretion inhibitor and potassium-competitive acid blocker (P-CAB).

Career Highlights

Throughout his career, Lei Chen has worked with prominent pharmaceutical companies, including Jiangsu Hansoh Pharmaceutical Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His work in these organizations has positioned him as a valuable contributor to the pharmaceutical innovation landscape.

Collaborations

In his professional journey, Lei Chen has collaborated with notable coworkers such as Jiong Lan and Piaoyang Sun. Their combined efforts in research and development have furthered the advancement of medical therapies and innovation in the pharmaceutical industry.

Conclusion

In summary, Lei Chen is a distinguished inventor whose patents reflect a deep understanding of pharmaceutical chemistry and its potential to improve patient care. His innovative approaches to drug development, particularly in the area of RORγ inhibition and pyrrole sulfonamide derivatives, underscore his commitment to advancing medical science and enhancing therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…